Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HLA crossroad in tumor immunology.

Human immunology - 1 Jan 2000

Algarra I, Cabrera T, Garrido F

Abstract excerpt

It is generally accepted that human and experimental tumor cells can lose major histocompatibility complex (MHC) class I molecules. These human leukocyte antigen (HLA) losses are detected when the primary tumor breaks the basal membrane, invades the surrounding tissues, and starts to metastasize. These altered HLA class I phenotypes probably constitute the major tumor escape mechanism facing anti-tumor T-cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histocompatibility Antigens Class I
Share to Immunotherapy
Share to Killer Cells, Natural

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasms

Share to Phenotype

Share to T-Lymphocytes

Share to Tumor Escape

Source

Identifiers

PMID: 10658979
DOI: 10.1016/s0198-8859(99)00156-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HLA crossroad in tumor immunology.PMID 10658979Read ↗

Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms.Semantic proximity Read ↗

Role of altered expression of HLA class I molecules in cancer progression.Semantic proximity Read ↗

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.Semantic proximity Read ↗

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implicationsSemantic proximity Read ↗

Deregulation of HLA-I in cancer and its central importance for immunotherapySemantic proximity Read ↗

The biological consequences of altered MHC class I expression in tumours.Semantic proximity Read ↗

Different mechanisms can lead to the same altered HLA class I phenotype in tumors.Semantic proximity Read ↗

Targeting HLA class I expression to increase tumor immunogenicitySemantic proximity Read ↗

Altered MHC class I antigens in tumors.Semantic proximity Read ↗

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationSemantic proximity Read ↗

Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyondSemantic proximity Read ↗

Tumour immunology, vaccination and escape strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.